Potential stages for prostate cancer prevention with selenium: implications for cancer survivors
- PMID: 19318549
- PMCID: PMC2909787
- DOI: 10.1158/0008-5472.CAN-08-4359
Potential stages for prostate cancer prevention with selenium: implications for cancer survivors
Abstract
The lack of treatment for "worried well" patients with high-grade prostatic intraepithelial neoplasia combined with issues of recurrence and hormone resistance in prostate cancer survivors remains a major public health obstacle. The long latency of prostate cancer development provides an ample opportunity to intervene with mechanistically based chemopreventive agents at various stages of disease progression. Our rationale for selenium intervention is based on current mechanistic knowledge derived solely from preclinical investigations. Clearly, there is sufficient scientific support for its entry into current clinical trials, the outcome of which will be highly valuable in assessing whether selenium can be recommended for cancer survivors.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
References
-
- Cancer facts and figures 2008. Atlanta: American Cancer Socitey; 2008.
-
- Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2193–2203. - PubMed
-
- Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Cancer Reviews. 2001;1:34–35. - PubMed
-
- Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington D.C.: World Cancer Research Fund/American Institute for Cancer Research; 2007.
-
- Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–2490. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical